Paris-Est Créteil Val-de-Marne University was inaugurated in 1970. It is a multidisciplinary centre based principally in Créteil . The university offers training in law, arts and humanities, science and technology, economics and development, administration and exchange, educational science, as well as social science. Val de Marne University is composed of seven departements and seven institutes situated in Vitry-sur-Seine , Seine-et-Marne, and in the 14th arrondissement of Paris. Wikipedia.
French Institute of Health, Medical Research, Montpellier University, Assistance Publique Hopitaux De Paris, University Paris Est Creteil and University of Angers | Date: 2016-10-17
The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.
University Paris Est Creteil, French National Center for Scientific Research, French Institute of Health and Medical Research | Date: 2015-03-20
The present invention relates to hybrid fumarate-CO-releasing molecules capable of increasing heme oxygenase-1 (HO-1) activity and HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases.
French Institute of Health, Medical Research, University Paris Diderot and University Paris Est Creteil | Date: 2017-02-07
The present invention relates methods and compositions for preventing or treating various immune diseases including graft-versus-host disease (GVHD) using populations or compositions of immunoregulatory T cells specific for an irrelevant antigen; such cells being activated in vivo by a simultaneous, separate or sequential administration of said antigen.
Agency: European Commission | Branch: H2020 | Program: BBI-RIA | Phase: BBI.VC1.R1-2015 | Award Amount: 6.71M | Year: 2016
Zelcor project aims at demonstrating the feasibility of transforming lignocellulose biorefinery recalcitrant side streams into high added-value biobased products, including fine chemicals. Its concept is to combine chemical and enzymatic catalysis with insects-based biological conversion, within a biorefinery integrated approach. The project is conceived to avoid waste production by recycling waste bio-based products and improve the sustainability of existing second generation biorefineries. It addresses three types of recalcitrant raw materials: lignocellulosic residues from ethanol production, lignins dissolved during pulping process and lignin-like humins formed by sugars conversion. Enzymatic and process engineering will be implemented to design efficient conversion routes and permit technological breakthroughs. A transversal platform for the characterisation of biomolecules will be settled to identify bio-products of commercial interest among lignins and humins multifunctional nanoparticles, phenolic antioxidants, insects-based chitosans and aromatic chemical intermediates. Thanks to this platform, Zelcor will enhance knowledge of the structure-function relationships and the mechanisms involved in recalcitrant raw materials catalytic depolymerisation and bioconversion. Demonstration of the approach feasibility will be performed by process scaling-up, formulation of end-product prototypes and value chain sustainability and safety assessment. The presence of industrial partners all along the value chains, from lignocellulosic feedstock to end products, will facilitate demonstration activities and technological transfers. With this strong industry drive, Zelcor will lead to large scale production of biomolecules for cosmetics, packaging and chemical industry, as well as novel biocatalysts. Zelcor is a 6.7M collaborative project, 49% of which for SMEs (43% EC grant). It gathers 18 organisations from 8 countries, including 6 academia, 8 SMEs, and 3 corporations.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: FETOPEN-01-2016-2017 | Award Amount: 3.99M | Year: 2017
ArrestAD proposes a novel and visionary thinking resulting from the demonstration of the central role of a particular heparan sulfate species at the intracellular level in neurons and in circulating cells in the molecular pathology of Alzheimers disease (AD). AD is a societal challenge for which there is neither prevention nor possible cure. Research in the field has long been refining classic concepts based on the aggregation of A and tau through initial seeding and then spreading. Our vision is different and based on the demonstration that tau abnormal phosphorylation and aggregation is triggered by the interaction of tau with heparan sulfates internalized in neurons and circulating cells only in AD [UPEC R.1; P.1,2]. Based in this new concept, ArrestAD will establish links between AD genetics, disease hallmarks, and altered traffic and intracellular accumulation of heparan sulfates to generate new knowledge underpinning the development of new strategies for detection and treatment of AD. This will open to radically new technologies addressing two major objectives: 1) proving that specific and early diagnosis of AD is possible in circulating cells, and 2) demonstrating that a new class of drug candidates are able to preventing and/or arresting AD-neurodegeneration. To reach these objectives, ArrestAD brings together internationally recognized experts in AD clinics and diagnosis, in heparan sulfate biology, transcriptomics, interactomics, carbohydrate chemistry, enzymology, cell biology, animal experimentation with AD models, and a SME specialized in the development of diagnosis kits using circulating cells. The high-risk character of this joint science and technology research is offset by the multidisciplinary nature of the Consortium and the high socio-economic gain resulting from success. Based in this technology, we will build a diverse portfolio of future projects that will result in a long-term benefit for citizens, economy and society.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.3.1-1 | Award Amount: 7.70M | Year: 2014
In 2010, 30 million Europeans were affected by depression and their number is still growing. Half of Europeans in need of mental care for depression do not have access to care services, do not always receive evidence-based treatments, are confronted with long waiting lists or high care expenditures. Internet-based treatment has the potential to addresses the drawbacks of standard care and keep depression treatment of high quality and affordable. E-COMPARED will conduct comparative effectiveness research in routine specialized mental care settings on the (cost-) effectiveness of internet-based treatment for depression in comparison with standard care. Health care systems, and -policies, existing ICT infrastructures and their uptake will be taken into account. E-COMPARED aims to 1)Evaluate EU mental health policies/guidelines for standard and internet-based care for depression in specialized care settings in countries with different health care systems and access levels of standard and internet-based care; 2)Compare clinical efficacy and cost-effectiveness of internet-based treatment and treatment as usual within controlled research settings, 3)Carry out pragmatic randomized controlled trials to study how internet-based depression treatment can be effectively implemented within routine specialized care settings, 4)Predict which patient groups could benefit from internet-based treatment vs. standard treatment by modeling patient characteristics; 5)Develop evidence based recommendations on how internet-based depression treatment can be cost-effectively integrated into routine specialized care systems for depression in EU mental health care systems, and develop a business case to ensure structural implementation of these services. E-COMPARED is multidisciplinary (psychology, HTA, ICT, care) and its members have a front runners position in internet-based treatment for common mental health disorders, e.g. through participating in FP7 projects (ICT4Depression, ROAMER).
Lemaitre A.,University Paris Est Creteil
Physical Review Letters | Year: 2014
We show that in deeply supercooled liquids, structural relaxation proceeds via the accumulation of Eshelby events, i.e. local rearrangements that create long-ranged and anisotropic stresses in the surrounding medium. Such events must be characterized using tensorial observables and we construct an analytical framework to probe their correlations using local stress data. By analyzing numerical simulations, we then demonstrate that events are power-law correlated in space, with a time-dependent amplitude which peaks at the alpha relaxation time τα. This effect, which becomes stronger near the glass transition, results from the increasingly important role of local stress fluctuations in facilitating relaxation events. Our finding precludes the existence of any length scale beyond which the relaxation process decorrelates. © 2014 American Physical Society.
Leveziel N.,University Paris Est Creteil
American journal of ophthalmology | Year: 2013
To analyze the contribution of fluorescein angiography (FA) and spectral-domain optical coherence tomography (SD OCT) to the diagnosis of recent choroidal neovascularization (CNV) associated with high myopia. Retrospective, observational case series. Ninety eyes of 73 highly myopic patients (refractive error ≥-6 diopters) with CNV in 1 or both eyes were included. Epidemiologic features, refractive error, fundus examination, fluorescein angiography, and SD OCT findings at onset of CNV were analyzed. Mean age at onset of CNV was 54.4 ± 14 years. CNV was bilateral in 17 of 73 cases. Mean refractive error was -13.9 ± 5.2 diopters. Myopic CNV was associated more frequently with patchy or geographic atrophy (P = .019). CNV was associated with exudative features on fluorescein angiography in 82% of cases (64/78), and on SD OCT in 48.6% of cases (36/74). There was no agreement about signs of active CNV between these 2 imaging methods (κ = 25.7 ± 10%; P = .0044). CNV area was significantly smaller in younger patients (<55 years) than in older patients (0.57 mm(2) vs 1.21 mm(2), respectively; P = .023). Exudative features of myopic CNV are more obvious on FA than on SD OCT, suggesting that fluorescein angiography should be performed when new-onset myopic CNV is suspected. Myopic CNV occurring in older patients (≥55 years) is larger than those seen in younger patients and resembles CNV associated with age-related macular degeneration. This suggests an overlap between myopic CNV in older patients and age-related macular degeneration. Copyright © 2013 Elsevier Inc. All rights reserved.
French Institute of Health, Medical Research, University Paris Est Creteil and Assistance Publique Hopitaux De Paris | Date: 2016-06-06
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-EJD | Phase: MSCA-ITN-2014-EJD | Award Amount: 3.92M | Year: 2015
The Advanced Biological Waste-to-Energy Technologies (ABWET) EJD provides education and research at PhD level on environmental technologies that convert waste materials into bioenergy, training doctoral candidates to think globally and work in multidisciplinary research teams. This makes ABWET alumni attractive for European universities and industry, able to contribute to solving the global challenges of waste management, energy scarcity and sustainable development. ABWET is centred around environmental technologies for treatment of waste, with a focus on anaerobic treatment processes, valorisation of the digestate and biofuel clean-up. ABWET focuses on fundamental and applied research of different treatment technologies as well as on the development of innovative recovery and reuse technologies with enhanced market potential. A strong industrial participation will bring a close connection to practical problems. ABWET provides its doctoral candidates training through research stipulated in a PhD proposal and through education detailed in an Individual Training and Supervision Plan, whereas a career development plan provides guidance on career paths, the labour market and professional development. The ABWET EJD aims to continue the successful Erasmus Mundus Joint Doctorate Environmental Technologies for Contaminated Soils, Sediments and Solid Waste (ETeCoS3), which developed a joint PhD education and research curriculum with joint selection, supervision and PhD defence procedures. The current three ETeCoS3 beneficiaries issue a fully joint PhD degree in Environmental Technology, recognised by the respective academic boards. ABWET will expand the degree awarding consortium with a 4th beneficiary, Tampere University of Technology Finland. A special Work Package is dedicated to adapt the ETeCoS3 consortium agreement and streamline the PhD graduation requirements so that ABWET graduates will receive a joint doctoral degree issued by the 4 beneficiaries.